164 related articles for article (PubMed ID: 32781455)
1. Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity.
van Schaik J; Begijn DGA; van Iersel L; Vergeer Y; Hoving EW; Peeters B; van Santen HM
Obes Facts; 2020; 13(4):361-370. PubMed ID: 32781455
[TBL] [Abstract][Full Text] [Related]
2. The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review.
Ng VWW; Gerard G; Koh JJK; Loke KY; Lee YS; Ng NBH
Clin Obes; 2024 Jun; 14(3):e12642. PubMed ID: 38273176
[TBL] [Abstract][Full Text] [Related]
3. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.
Kelly AS; Rudser KD; Nathan BM; Fox CK; Metzig AM; Coombes BJ; Fitch AK; Bomberg EM; Abuzzahab MJ
JAMA Pediatr; 2013 Apr; 167(4):355-60. PubMed ID: 23380890
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
Roth CL; Perez FA; Whitlock KB; Elfers C; Yanovski JA; Shoemaker AH; Abuzzahab MJ
Diabetes Obes Metab; 2021 Feb; 23(2):363-373. PubMed ID: 33026160
[TBL] [Abstract][Full Text] [Related]
5. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.
Nathan BM; Rudser KD; Abuzzahab MJ; Fox CK; Coombes BJ; Bomberg EM; Kelly AS
Clin Obes; 2016 Feb; 6(1):73-8. PubMed ID: 26683756
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
[TBL] [Abstract][Full Text] [Related]
7. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
[TBL] [Abstract][Full Text] [Related]
8. MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.
Perez FA; Elfers C; Yanovski JA; Shoemaker AH; Abuzzahab MJ; Roth CL
Diabetes Obes Metab; 2021 Jul; 23(7):1532-1541. PubMed ID: 33651438
[TBL] [Abstract][Full Text] [Related]
9. A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
Weghuber D; Forslund A; Ahlström H; Alderborn A; Bergström K; Brunner S; Cadamuro J; Ciba I; Dahlbom M; Heu V; Hofmann J; Kristinsson H; Kullberg J; Ladinger A; Lagler FB; Lidström M; Manell H; Meirik M; Mörwald K; Roomp K; Schneider R; Vilén H; Widhalm K; Zsoldos F; Bergsten P
Pediatr Obes; 2020 Jul; 15(7):e12624. PubMed ID: 32062862
[TBL] [Abstract][Full Text] [Related]
10. The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes.
Tee SA; Tsatlidis V; Razvi S
Clin Endocrinol (Oxf); 2023 Oct; 99(4):401-408. PubMed ID: 36843143
[TBL] [Abstract][Full Text] [Related]
11. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
12. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.
Shoemaker AH; Silver HJ; Buchowski M; Slaughter JC; Yanovski JA; Elfers C; Roth CL; Abuzzahab MJ
Int J Obes (Lond); 2022 Mar; 46(3):623-629. PubMed ID: 34975146
[TBL] [Abstract][Full Text] [Related]
13. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases.
Zoicas F; Droste M; Mayr B; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 May; 168(5):699-706. PubMed ID: 23392214
[TBL] [Abstract][Full Text] [Related]
15. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
16. A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity.
Lomenick JP; Buchowski MS; Shoemaker AH
Obesity (Silver Spring); 2016 Jun; 24(6):1222-5. PubMed ID: 27133664
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
18. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
[TBL] [Abstract][Full Text] [Related]
20. Treatment with glucagon-like Peptide-1 agonist exendin-4 in a patient with hypothalamic obesity secondary to intracranial tumor.
Simmons JH; Shoemaker AH; Roth CL
Horm Res Paediatr; 2012; 78(1):54-8. PubMed ID: 22831918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
